

Supplementary Table 2 . Characteristics of the patients with an inconclusive SLT

	No Primary Aldosteronism (<i>n</i> = 136)	Primary Aldosteronism (<i>n</i> = 154)
Age (years)	54 (46-63)	58 (48-63)
Gender (male:female) – n (%)	32:38 (46:54)	29:16 (64:36)
Plasma sodium concentration (mmol/L) ^a	141 (140-143)	141 (140-142)
PRC before saline infusion (mU/L) ^b	7.3 (5.0-12.0)	4.4 (3.0-6.5)
PRC after saline infusion (mU/L) ^c	5.9 (4.0-8.5)	3.1 (3.0-4.3)
PAC before saline infusion (pmol/L) ^d	320 (280-463)	450 (350-547)
PAC after saline infusion (pmol/L)	180 (160-210)	240 (220-270)
Office systolic blood pressure (mm Hg)	158 (145-173)	160 (139-169)
Office diastolic blood pressure (mm Hg)	94 (86-104)	90 (81-101)
Antihypertensive medication (DDD)	0.83 (0.00-2.00)	2.33 (0.83-4.16)
Plasma bicarbonate concentration (mmol/L) ^e	26.5 (25.2-29.0)	26.6 (25.2-29.2)
Potassium supplementation (mmol/day) ^f	0 (0-0)	24 (0-48)
Plasma potassium concentration (mmol/L) ^f	3.8 (3.6-4.0)	3.6 (3.4-3.8)
Hypokalemia prior to SLT – n (%) ^f	11 (16)	15 (33)
Screening ARR (pmol/mU) ^g	56.8 (41.0-94.3)	109.8 (76.0-162.0)

Data are expressed as median (interquartile range) unless otherwise specified. DDD, defined daily dose; SLT, salt loading test; PAC, plasma aldosterone concentration; PRC, plasma renin concentration; ARR,

aldosterone-to-renin ratio; Hypokalemia is defined as plasma potassium concentration <3.5 mmol/l.

^a no PA n=130; PA n=152

^b no PA n=133; PA n=151

^c no PA n=132; PA n=148

^d PA n=152

^e no PA n=40; PA n=53

^f no PA n=133; PA n=148

^g PA n=153
